Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Scientists uncover how cancer cells hide from immune system

By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Content from other channels on our network

Construction begins on WA gallium project

Latest AEMO report on future grid stability released

UNSW engineers awarded grant for critical renewables research

Australia–Japan laser a new step towards advanced defence manufacturing

Robots have a positive effect on employment and productivity: report

Government invests $1.5m in regional science partnerships

Desalination marine works conclude at Belmont

Zip Water releases 2025 Sustainability Report

Australia's EV fleet transition will be won or lost at the depot

Smart stormwater system removes harmful pollutants

Integrated bulk handling system boosts gluten-free food production

Snack brand Nibblish focused on sustainable business model

Making cultivated meat more viable by re-using waste

WA-based Brownes Dairy is back on the market

New Chair of the Western Australian Meat Industry Authority Board